Seres Therapeutics Inc MCRB
News
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
Seres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection Treatment